Navidea Biopharmaceuticals, Inc. (NAVB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2022 | 427.34 Thousand USD | 182.72% |
| 2021 | 151.15 Thousand USD | -10.98% |
| 2020 | 169.79 Thousand USD | 118.84% |
| 2019 | -901.33 Thousand USD | -90134000.0% |
| 2018 | 1.00 USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 1.47 Million USD | 125.27% |
| 2015 | 652.9 Thousand USD | -29.97% |
| 2014 | 932.38 Thousand USD | -58.23% |
| 2013 | 2.23 Million USD | 650.4% |
| 2012 | 297.5 Thousand USD | -63.79% |
| 2011 | 821.54 Thousand USD | -43.68% |
| 2010 | 1.45 Million USD | 27.53% |
| 2009 | 1.14 Million USD | 18.9% |
| 2008 | 961.86 Thousand USD | -22.27% |
| 2007 | 1.23 Million USD | 7.19% |
| 2006 | 1.15 Million USD | 43.63% |
| 2005 | 803.7 Thousand USD | -6.0% |
| 2004 | 855.02 Thousand USD | -15.2% |
| 2003 | 1 Million USD | -15.4% |
| 2002 | 1.19 Million USD | -16.7% |
| 2001 | 1.43 Million USD | 52.04% |
| 2000 | 941.12 Thousand USD | -17.04% |
| 1999 | 1.13 Million USD | -28.15% |
| 1998 | 1.57 Million USD | 282.28% |
| 1997 | 413.02 Thousand USD | 90.97% |
| 1996 | 216.27 Thousand USD | -56.75% |
| 1995 | 500 Thousand USD | 0.0% |
| 1994 | 500 Thousand USD | -28.57% |
| 1993 | 700 Thousand USD | 250.0% |
| 1992 | 200 Thousand USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 Q3 | 460.74 Thousand USD | 0.0% |
| 2023 Q1 | 460.63 Thousand USD | 7.79% |
| 2023 Q2 | 460.74 Thousand USD | 0.02% |
| 2022 Q3 | 193.8 Thousand USD | -38.6% |
| 2022 Q2 | 315.67 Thousand USD | -2.27% |
| 2022 Q1 | 322.99 Thousand USD | 113.68% |
| 2022 FY | 427.34 Thousand USD | 182.72% |
| 2022 Q4 | 427.34 Thousand USD | 120.5% |
| 2021 Q1 | 166.24 Thousand USD | -2.09% |
| 2021 Q2 | 178.83 Thousand USD | 7.57% |
| 2021 Q3 | 178.93 Thousand USD | 0.06% |
| 2021 Q4 | 151.15 Thousand USD | -15.53% |
| 2021 FY | 151.15 Thousand USD | -10.98% |
| 2020 Q1 | -1.69 Million USD | -88.1% |
| 2020 Q3 | -820.21 Thousand USD | 0.0% |
| 2020 FY | 169.79 Thousand USD | 118.84% |
| 2020 Q4 | 169.79 Thousand USD | 120.7% |
| 2020 Q2 | - USD | 100.0% |
| 2019 Q3 | -145.81 Thousand USD | 29.51% |
| 2019 Q1 | 1.00 USD | 0.0% |
| 2019 Q2 | -206.86 Thousand USD | -20686400.0% |
| 2019 FY | -901.33 Thousand USD | -90134000.0% |
| 2019 Q4 | -901.33 Thousand USD | -518.13% |
| 2018 Q4 | 1.00 USD | 0.0% |
| 2018 FY | 1.00 USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q3 | 1.00 USD | 0.0% |
| 2017 Q2 | 1.00 USD | -99.87% |
| 2017 Q1 | 748.00 USD | -99.95% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | -100.0% |
| 2017 FY | - USD | -100.0% |
| 2016 Q2 | 769.82 Thousand USD | -14.36% |
| 2016 Q1 | 898.93 Thousand USD | 37.68% |
| 2016 Q4 | 1.47 Million USD | 82.74% |
| 2016 Q3 | 804.88 Thousand USD | 4.55% |
| 2016 FY | 1.47 Million USD | 125.27% |
| 2015 Q4 | 652.9 Thousand USD | -25.57% |
| 2015 Q1 | 571.6 Thousand USD | -38.69% |
| 2015 FY | 652.9 Thousand USD | -29.97% |
| 2015 Q2 | 1.19 Million USD | 109.08% |
| 2015 Q3 | 877.18 Thousand USD | -26.6% |
| 2014 Q1 | 2.11 Million USD | -5.31% |
| 2014 FY | 932.38 Thousand USD | -58.23% |
| 2014 Q2 | 1.9 Million USD | -9.85% |
| 2014 Q4 | 932.38 Thousand USD | -16.77% |
| 2014 Q3 | 1.12 Million USD | -41.22% |
| 2013 Q2 | 1.32 Million USD | 53.33% |
| 2013 Q3 | 2.04 Million USD | 53.62% |
| 2013 FY | 2.23 Million USD | 650.4% |
| 2013 Q4 | 2.23 Million USD | 9.28% |
| 2013 Q1 | 867.26 Thousand USD | 191.52% |
| 2012 Q3 | 641 Thousand USD | -30.21% |
| 2012 Q1 | 918.5 Thousand USD | 11.8% |
| 2012 Q4 | 297.5 Thousand USD | -53.59% |
| 2012 FY | 297.5 Thousand USD | -63.79% |
| 2012 Q2 | 918.5 Thousand USD | 0.0% |
| 2011 Q2 | 1.64 Million USD | 10.02% |
| 2011 Q4 | 821.54 Thousand USD | -2.68% |
| 2011 FY | 821.54 Thousand USD | -43.68% |
| 2011 Q1 | 1.49 Million USD | 2.33% |
| 2011 Q3 | 844.2 Thousand USD | -48.59% |
| 2010 Q1 | 1.36 Million USD | 19.04% |
| 2010 FY | 1.45 Million USD | 27.53% |
| 2010 Q4 | 1.45 Million USD | -26.14% |
| 2010 Q3 | 1.97 Million USD | 48.84% |
| 2010 Q2 | 1.32 Million USD | -2.54% |
| 2009 FY | 1.14 Million USD | 18.9% |
| 2009 Q1 | 976.13 Thousand USD | 1.48% |
| 2009 Q4 | 1.14 Million USD | 10.14% |
| 2009 Q3 | 1.03 Million USD | -6.57% |
| 2009 Q2 | 1.11 Million USD | 13.86% |
| 2008 Q1 | 1.08 Million USD | -12.42% |
| 2008 Q4 | 961.86 Thousand USD | 22.35% |
| 2008 Q2 | 1.04 Million USD | -3.24% |
| 2008 FY | 961.86 Thousand USD | -22.27% |
| 2008 Q3 | 786.14 Thousand USD | -25.03% |
| 2007 Q4 | 1.23 Million USD | 20.73% |
| 2007 FY | 1.23 Million USD | 7.19% |
| 2007 Q1 | 1.04 Million USD | -9.27% |
| 2007 Q2 | 1.13 Million USD | 8.74% |
| 2007 Q3 | 1.02 Million USD | -10.0% |
| 2006 Q2 | 812.58 Thousand USD | 1.46% |
| 2006 Q1 | 800.91 Thousand USD | -0.35% |
| 2006 FY | 1.15 Million USD | 43.63% |
| 2006 Q4 | 1.15 Million USD | 10.37% |
| 2006 Q3 | 1.04 Million USD | 28.71% |
| 2005 Q2 | 756.9 Thousand USD | -12.0% |
| 2005 Q4 | 803.7 Thousand USD | -1.71% |
| 2005 FY | 803.7 Thousand USD | -6.0% |
| 2005 Q1 | 860.08 Thousand USD | 0.59% |
| 2005 Q3 | 817.72 Thousand USD | 8.03% |
| 2004 Q3 | 946.66 Thousand USD | -5.19% |
| 2004 FY | 855.02 Thousand USD | -15.2% |
| 2004 Q1 | 921.45 Thousand USD | -8.62% |
| 2004 Q2 | 998.51 Thousand USD | 8.36% |
| 2004 Q4 | 855.02 Thousand USD | -9.68% |
| 2003 FY | 1 Million USD | -15.4% |
| 2003 Q4 | 1 Million USD | -13.6% |
| 2003 Q3 | 1.16 Million USD | 22.44% |
| 2003 Q2 | 953.09 Thousand USD | -1.71% |
| 2003 Q1 | 969.69 Thousand USD | -18.64% |
| 2002 Q4 | 1.19 Million USD | -6.08% |
| 2002 Q1 | 1.32 Million USD | -7.51% |
| 2002 Q2 | 1.52 Million USD | 15.47% |
| 2002 Q3 | 1.26 Million USD | -16.95% |
| 2002 FY | 1.19 Million USD | -16.7% |
| 2001 Q4 | 1.43 Million USD | -13.35% |
| 2001 Q1 | 1.3 Million USD | 38.43% |
| 2001 FY | 1.43 Million USD | 52.04% |
| 2001 Q2 | 1.09 Million USD | -15.81% |
| 2001 Q3 | 1.65 Million USD | 50.56% |
| 2000 Q3 | 453.32 Thousand USD | 36.58% |
| 2000 Q1 | 488.66 Thousand USD | -56.76% |
| 2000 FY | 941.12 Thousand USD | -17.04% |
| 2000 Q4 | 941.12 Thousand USD | 107.61% |
| 2000 Q2 | 331.89 Thousand USD | -32.08% |
| 1999 Q1 | 1.5 Million USD | -5.0% |
| 1999 Q3 | 1.94 Million USD | 29.33% |
| 1999 Q4 | 1.13 Million USD | -41.75% |
| 1999 FY | 1.13 Million USD | -28.15% |
| 1999 Q2 | 1.5 Million USD | 0.0% |
| 1998 Q2 | 1 Million USD | -16.67% |
| 1998 FY | 1.57 Million USD | 282.28% |
| 1998 Q4 | 1.57 Million USD | 97.36% |
| 1998 Q1 | 1.2 Million USD | 190.54% |
| 1998 Q3 | 800 Thousand USD | -20.0% |
| 1997 Q2 | 600 Thousand USD | 0.0% |
| 1997 Q3 | 300 Thousand USD | -50.0% |
| 1997 Q4 | 413.02 Thousand USD | 37.67% |
| 1997 Q1 | 600 Thousand USD | 177.43% |
| 1997 FY | 413.02 Thousand USD | 90.97% |
| 1996 Q4 | 216.27 Thousand USD | -63.95% |
| 1996 Q1 | 400 Thousand USD | -20.0% |
| 1996 Q2 | 300 Thousand USD | -25.0% |
| 1996 Q3 | 600 Thousand USD | 100.0% |
| 1996 FY | 216.27 Thousand USD | -56.75% |
| 1995 Q2 | 400 Thousand USD | -20.0% |
| 1995 Q4 | 500 Thousand USD | 0.0% |
| 1995 Q1 | 500 Thousand USD | 0.0% |
| 1995 FY | 500 Thousand USD | 0.0% |
| 1995 Q3 | 500 Thousand USD | 25.0% |
| 1994 FY | 500 Thousand USD | -28.57% |
| 1994 Q3 | 700 Thousand USD | 0.0% |
| 1994 Q4 | 500 Thousand USD | -28.57% |
| 1994 Q2 | 700 Thousand USD | 0.0% |
| 1994 Q1 | 700 Thousand USD | 0.0% |
| 1993 Q4 | 700 Thousand USD | 133.33% |
| 1993 FY | 700 Thousand USD | 250.0% |
| 1993 Q1 | 400 Thousand USD | 100.0% |
| 1993 Q2 | 300 Thousand USD | -25.0% |
| 1993 Q3 | 300 Thousand USD | 0.0% |
| 1992 FY | 200 Thousand USD | 0.0% |
| 1992 Q3 | 200 Thousand USD | 0.0% |
| 1992 Q4 | 200 Thousand USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -1.18 Million USD | 136.093% |
| Ampio Pharmaceuticals, Inc. | 1.00 USD | -42734300.0% |
| Armata Pharmaceuticals, Inc. | - USD | -Infinity% |
| Actinium Pharmaceuticals, Inc. | - USD | -Infinity% |
| Azitra, Inc. | -215.21 Thousand USD | 298.562% |
| Can-Fite BioPharma Ltd. | - USD | -Infinity% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | - USD | -Infinity% |
| CEL-SCI Corporation | 2.24 Million USD | 80.991% |
| iBio, Inc. | - USD | -Infinity% |
| Lineage Cell Therapeutics, Inc. | - USD | -Infinity% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | - USD | -Infinity% |
| NovaBay Pharmaceuticals, Inc. | 2.87 Million USD | 85.146% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | - USD | -Infinity% |
| BiomX Inc. | - USD | -Infinity% |
| BiomX Inc. | - USD | -Infinity% |
| Protalix BioTherapeutics, Inc. | 19.04 Million USD | 97.756% |
| Palatin Technologies, Inc. | - USD | -Infinity% |
| Scorpius Holdings, Inc. | 909.15 Thousand USD | 52.996% |
| Theriva Biologics, Inc. | - USD | -Infinity% |